Clinical Trials Logo

Type I Hypersensitivity clinical trials

View clinical trials related to Type I Hypersensitivity.

Filter by:

NCT ID: NCT00113750 Completed - Clinical trials for Type I Hypersensitivity

Induction of Immunogenicity With Different Doses of TreeMATA in Subjects Allergic to Tree Pollen

Start date: July 2005
Phase: Phase 2
Study type: Interventional

Tree MATA (modified pollen allergen tyrosine adsorbate) has been developed to provide pre-seasonal specific immunotherapy for patients with hypersensitivity to tree (birch, alder, and hazel) pollen. Different doses of Tree MATA will be administered and immunological changes following this treatment will be assessed.

NCT ID: NCT00110786 Completed - Clinical trials for Type I Hypersensitivity

Investigation of Efficacy and Safety of Ragweed MATAMPL, Pollinex-R and Placebo in Patients With Ragweed Allergy

Start date: May 2005
Phase: Phase 2
Study type: Interventional

Ragweed MATAMPL has been developed to provide pre-seasonal specific immunotherapy for patients with hypersensitivity to ragweed pollen (hay fever). This novel formulation is designed to provide a vaccine that will be efficacious with only four escalating dose injections administered before the start of the pollen season. In this study, the safety and efficacy of Ragweed MATAMPL will be assessed by exposing allergic subjects to Ragweed pollen in an environmental exposure chamber (EEC). Patient symptomatic response to pollen and patient quality of life in the EEC will be determined.

NCT ID: NCT00107705 Completed - Clinical trials for Type I Hypersensitivity

Assessment of Residual Allergenicity of Tree (Birch, Hazel, and Alder) Pollen Allergoid Using Skin Prick Testing

Start date: April 2005
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the residual allergenicity of Tree MATA (modified pollen allergen tyrosine adsorbate) by skin prick testing. This is done by a comparison of the wheal response after skin prick testing with aqueous native and modified allergen, modified tyrosine adsorbed allergen and Tree MATA MPL (modified tyrosine adsorbed + MPL [Monophosphoryl Lipid A]).

NCT ID: NCT00104390 Completed - Clinical trials for Type I Hypersensitivity

Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing

Start date: March 2005
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the residual allergenicity of Grass MATA (modified pollen allergen tyrosine adsorbate) by skin prick testing. This is done by a comparison of the wheal response after skin prick testing with aqueous native and modified allergen, modified tyrosine adsorbed allergen and Grass MATA MPL (modified tyrosine adsorbed + MPL).

NCT ID: NCT00104377 Completed - Clinical trials for Type I Hypersensitivity

Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen

Start date: March 2005
Phase: Phase 2
Study type: Interventional

Grass MATA (modified pollen allergen tyrosine adsorbate) has been developed to provide pre-seasonal specific immunotherapy for patients with hypersensitivity to grass and rye pollen. Different doses of Grass MATA will be administered and immunological changes following this treatment will be assessed.